
LINK . SPRINGER . COM {
}
Detected CMS Systems:
- Pivotx (1 occurrences)
Title:
A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer | Breast Cancer Research and Treatment
Description:
Bevacizumab in combination with chemotherapy increases progression-free survival (PFS), but not overall survival when compared to chemotherapy alone in the treatment of metastatic breast cancer (MBC). Recently in November, 2011 the Food and drug administration revoked approval of bevacizumab in combination with paclitaxel for the treatment of MBC. The European Medicines Agency, in contrast, maintained its approval of bevacizumab in MBC. While neither agency considers health economics in their decision-making process, one of the greatest challenges in oncology practice today is to reconcile hard-won small incremental clinical benefits with exponentially rising costs. To inform policy-makers in the US, this study aimed to assess the cost-effectiveness of bevacizumab/paclitaxel in MBC, from a payer perspective. We created a decision analytical model using efficacy and adverse events data from the ECOG 2100 trial. Health utilities were derived from available literature. Costs were obtained from the Center for Medicare Services Drug Payment Table and Physician Fee Schedule and are represented in 2010 US dollars. Quality-adjusted life-years (QALY) and incremental cost-effectiveness ratio (ICER) were calculated. Sensitivity analyses were performed. Bevacizumab added 0.49 years of PFS and 0.135 QALY with an incremental cost of $100,300, and therefore a cost of $204,000 per year of PFS gained and an ICER of $745,000 per QALY. The main drivers of the model were drug acquisition cost, PFS, and health utility values. Using a threshold of $150,000/QALY, drug price would have to be reduced by nearly 80% or alternatively PFS increased by 10 months to make bevacizumab cost-effective. The results of the model were robust in sensitivity analyses. Bevacizumab plus paclitaxel is not cost-effective in treating MBC. Value-based pricing and the development of biomarkers to improve patient selection are needed to better define the role of the drug in this population.
Website Age:
28 years and 1 months (reg. 1997-05-29).
Matching Content Categories {📚}
- Health & Fitness
- Science
- Education
Content Management System {📝}
What CMS is link.springer.com built with?
Link.springer.com operates using PIVOTX.
Traffic Estimate {📈}
What is the average monthly size of link.springer.com audience?
🌠 Phenomenal Traffic: 5M - 10M visitors per month
Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Link.springer.com Make Money? {💸}
We can't tell how the site generates income.
Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.
Keywords {🔍}
cancer, bevacizumab, breast, article, treatment, metastatic, drug, research, paclitaxel, mbc, pubmed, google, scholar, privacy, cookies, combination, firstline, lopes, pfs, approval, health, qaly, cas, content, analysis, data, publish, search, december, montero, gilberto, cost, access, oncol, miami, information, log, journal, costbenefit, patients, avancha, stefan, glück, chemotherapy, economics, incremental, model, discover, society, recurrent,
Topics {✒️}
gov/downloads/newsevents/newsroom/ucm280546 month download article/chapter american cancer society uk/newsroom/pressreleases/bevacizumabformetastaticbreastcancer cost-benefit analysis incremental cost-effectiveness ratio advanced/metastatic recurrent nonsquamous metastatic breast cancer quality-adjusted life-years breast cancer indication health state utilities health utility values make bevacizumab cost-effective privacy choices/manage cookies improve patient selection line therapy full article pdf drug acquisition cost received research funding kiran avancha european medicines agency oncology practice today decision-making process physician fee schedule cohen mh miami miller school conditions privacy policy adverse events data inform policy-makers european economic area high-income countries phase iii study phase iii trial check access curr oncol rep instant access accepting optional cookies health utilities exponentially rising costs incremental cost decision analytical model article montero alternatively pfs increased usage analysis gilberto lopes journal finder publish colorectal cancer usa alberto article log author information authors
Questions {❓}
- Montero AJ, Escobar M, Lopes G, Gluck S, Vogel C (2011) Bevacizumab in the treatment of metastatic breast cancer: friend or foe?
- Will Antibody Biosimilars See the Light of Day?
Schema {🗺️}
WebPage:
mainEntity:
headline:A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer
description:Bevacizumab in combination with chemotherapy increases progression-free survival (PFS), but not overall survival when compared to chemotherapy alone in the treatment of metastatic breast cancer (MBC). Recently in November, 2011 the Food and drug administration revoked approval of bevacizumab in combination with paclitaxel for the treatment of MBC. The European Medicines Agency, in contrast, maintained its approval of bevacizumab in MBC. While neither agency considers health economics in their decision-making process, one of the greatest challenges in oncology practice today is to reconcile hard-won small incremental clinical benefits with exponentially rising costs. To inform policy-makers in the US, this study aimed to assess the cost-effectiveness of bevacizumab/paclitaxel in MBC, from a payer perspective. We created a decision analytical model using efficacy and adverse events data from the ECOG 2100 trial. Health utilities were derived from available literature. Costs were obtained from the Center for Medicare Services Drug Payment Table and Physician Fee Schedule and are represented in 2010 US dollars. Quality-adjusted life-years (QALY) and incremental cost-effectiveness ratio (ICER) were calculated. Sensitivity analyses were performed. Bevacizumab added 0.49 years of PFS and 0.135 QALY with an incremental cost of $100,300, and therefore a cost of $204,000 per year of PFS gained and an ICER of $745,000 per QALY. The main drivers of the model were drug acquisition cost, PFS, and health utility values. Using a threshold of $150,000/QALY, drug price would have to be reduced by nearly 80% or alternatively PFS increased by 10 months to make bevacizumab cost-effective. The results of the model were robust in sensitivity analyses. Bevacizumab plus paclitaxel is not cost-effective in treating MBC. Value-based pricing and the development of biomarkers to improve patient selection are needed to better define the role of the drug in this population.
datePublished:2011-12-27T00:00:00Z
dateModified:2011-12-27T00:00:00Z
pageStart:747
pageEnd:751
sameAs:https://doi.org/10.1007/s10549-011-1919-y
keywords:
Breast cancer
Cost-benefit analysis
Pharmacoeconomics
Bevacizumab
Economics
Metastatic breast cancer
QALY
Oncology
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1919-y/MediaObjects/10549_2011_1919_Fig1_HTML.gif
isPartOf:
name:Breast Cancer Research and Treatment
issn:
1573-7217
0167-6806
volumeNumber:132
type:
Periodical
PublicationVolume
publisher:
name:Springer US
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Alberto J. Montero
affiliation:
name:University of Miami Sylvester Comprehensive Cancer Center
address:
name:Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, USA
type:PostalAddress
type:Organization
type:Person
name:Kiran Avancha
affiliation:
name:University of Miami Miller School of Medicine Office of Research
address:
name:University of Miami Miller School of Medicine Office of Research, Miami, USA
type:PostalAddress
type:Organization
type:Person
name:Stefan Glück
affiliation:
name:University of Miami Sylvester Comprehensive Cancer Center
address:
name:Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, USA
type:PostalAddress
type:Organization
type:Person
name:Gilberto Lopes
affiliation:
name:Johns Hopkins Singapore International Medical Centre and Johns Hopkins University School of Medicine
address:
name:Johns Hopkins Singapore International Medical Centre and Johns Hopkins University School of Medicine, Singapore, Singapore
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer
description:Bevacizumab in combination with chemotherapy increases progression-free survival (PFS), but not overall survival when compared to chemotherapy alone in the treatment of metastatic breast cancer (MBC). Recently in November, 2011 the Food and drug administration revoked approval of bevacizumab in combination with paclitaxel for the treatment of MBC. The European Medicines Agency, in contrast, maintained its approval of bevacizumab in MBC. While neither agency considers health economics in their decision-making process, one of the greatest challenges in oncology practice today is to reconcile hard-won small incremental clinical benefits with exponentially rising costs. To inform policy-makers in the US, this study aimed to assess the cost-effectiveness of bevacizumab/paclitaxel in MBC, from a payer perspective. We created a decision analytical model using efficacy and adverse events data from the ECOG 2100 trial. Health utilities were derived from available literature. Costs were obtained from the Center for Medicare Services Drug Payment Table and Physician Fee Schedule and are represented in 2010 US dollars. Quality-adjusted life-years (QALY) and incremental cost-effectiveness ratio (ICER) were calculated. Sensitivity analyses were performed. Bevacizumab added 0.49 years of PFS and 0.135 QALY with an incremental cost of $100,300, and therefore a cost of $204,000 per year of PFS gained and an ICER of $745,000 per QALY. The main drivers of the model were drug acquisition cost, PFS, and health utility values. Using a threshold of $150,000/QALY, drug price would have to be reduced by nearly 80% or alternatively PFS increased by 10 months to make bevacizumab cost-effective. The results of the model were robust in sensitivity analyses. Bevacizumab plus paclitaxel is not cost-effective in treating MBC. Value-based pricing and the development of biomarkers to improve patient selection are needed to better define the role of the drug in this population.
datePublished:2011-12-27T00:00:00Z
dateModified:2011-12-27T00:00:00Z
pageStart:747
pageEnd:751
sameAs:https://doi.org/10.1007/s10549-011-1919-y
keywords:
Breast cancer
Cost-benefit analysis
Pharmacoeconomics
Bevacizumab
Economics
Metastatic breast cancer
QALY
Oncology
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1919-y/MediaObjects/10549_2011_1919_Fig1_HTML.gif
isPartOf:
name:Breast Cancer Research and Treatment
issn:
1573-7217
0167-6806
volumeNumber:132
type:
Periodical
PublicationVolume
publisher:
name:Springer US
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Alberto J. Montero
affiliation:
name:University of Miami Sylvester Comprehensive Cancer Center
address:
name:Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, USA
type:PostalAddress
type:Organization
type:Person
name:Kiran Avancha
affiliation:
name:University of Miami Miller School of Medicine Office of Research
address:
name:University of Miami Miller School of Medicine Office of Research, Miami, USA
type:PostalAddress
type:Organization
type:Person
name:Stefan Glück
affiliation:
name:University of Miami Sylvester Comprehensive Cancer Center
address:
name:Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, USA
type:PostalAddress
type:Organization
type:Person
name:Gilberto Lopes
affiliation:
name:Johns Hopkins Singapore International Medical Centre and Johns Hopkins University School of Medicine
address:
name:Johns Hopkins Singapore International Medical Centre and Johns Hopkins University School of Medicine, Singapore, Singapore
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
["Periodical","PublicationVolume"]:
name:Breast Cancer Research and Treatment
issn:
1573-7217
0167-6806
volumeNumber:132
Organization:
name:Springer US
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:University of Miami Sylvester Comprehensive Cancer Center
address:
name:Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, USA
type:PostalAddress
name:University of Miami Miller School of Medicine Office of Research
address:
name:University of Miami Miller School of Medicine Office of Research, Miami, USA
type:PostalAddress
name:University of Miami Sylvester Comprehensive Cancer Center
address:
name:Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, USA
type:PostalAddress
name:Johns Hopkins Singapore International Medical Centre and Johns Hopkins University School of Medicine
address:
name:Johns Hopkins Singapore International Medical Centre and Johns Hopkins University School of Medicine, Singapore, Singapore
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:Alberto J. Montero
affiliation:
name:University of Miami Sylvester Comprehensive Cancer Center
address:
name:Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, USA
type:PostalAddress
type:Organization
name:Kiran Avancha
affiliation:
name:University of Miami Miller School of Medicine Office of Research
address:
name:University of Miami Miller School of Medicine Office of Research, Miami, USA
type:PostalAddress
type:Organization
name:Stefan Glück
affiliation:
name:University of Miami Sylvester Comprehensive Cancer Center
address:
name:Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, USA
type:PostalAddress
type:Organization
name:Gilberto Lopes
affiliation:
name:Johns Hopkins Singapore International Medical Centre and Johns Hopkins University School of Medicine
address:
name:Johns Hopkins Singapore International Medical Centre and Johns Hopkins University School of Medicine, Singapore, Singapore
type:PostalAddress
type:Organization
email:[email protected]
PostalAddress:
name:Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, USA
name:University of Miami Miller School of Medicine Office of Research, Miami, USA
name:Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, USA
name:Johns Hopkins Singapore International Medical Centre and Johns Hopkins University School of Medicine, Singapore, Singapore
WebPageElement:
isAccessibleForFree:
cssSelector:.main-content
External Links {🔗}(54)
- How much does https://www.springernature.com/gp/authors net monthly?
- What's the financial intake of https://link.springernature.com/home/?
- https://order.springer.com/public/cart's financial summary
- Learn about the earnings of https://submission.springernature.com/new-submission/10549/3
- Earnings of https://www.springernature.com/gp/librarians/licensing/agc/journals
- How much does https://doi.org/10.1016%2FS1470-2045%2811%2970141-3 bring in each month?
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21958503's financial summary
- What's http://scholar.google.com/scholar_lookup?&title=Delivering%20affordable%20cancer%20care%20in%20high-income%20countries&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2811%2970141-3&volume=12&issue=10&pages=933-980&publication_year=2011&author=Sullivan%2CR&author=Peppercorn%2CJ&author=Sikora%2CK&author=Zalcberg%2CJ&author=Meropol%2CNJ&author=Amir%2CE&author=Khayat%2CD&author=Boyle%2CP&author=Autier%2CP&author=Tannock%2CIF's gross income?
- What's the income of https://doi.org/10.1007/s11912-011-0202-z?
- How much does https://doi.org/10.1634%2Ftheoncologist.12-3-356 gross monthly?
- How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17405901 make?
- Revenue of http://scholar.google.com/scholar_lookup?&title=FDA%20drug%20approval%20summary%3A%20bevacizumab%20plus%20FOLFOX4%20as%20second-line%20treatment%20of%20colorectal%20cancer&journal=Oncologist&doi=10.1634%2Ftheoncologist.12-3-356&volume=12&issue=3&pages=356-361&publication_year=2007&author=Cohen%2CMH&author=Gootenberg%2CJ&author=Keegan%2CP&author=Pazdur%2CR
- Find out how much https://doi.org/10.1634%2Ftheoncologist.12-6-713 earns monthly
- Earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17602060
- How much money does http://scholar.google.com/scholar_lookup?&title=FDA%20drug%20approval%20summary%3A%20bevacizumab%20%28Avastin%29%20plus%20Carboplatin%20and%20Paclitaxel%20as%20first-line%20treatment%20of%20advanced%2Fmetastatic%20recurrent%20nonsquamous%20non-small%20cell%20lung%20cancer&journal=Oncologist&doi=10.1634%2Ftheoncologist.12-6-713&volume=12&issue=6&pages=713-718&publication_year=2007&author=Cohen%2CMH&author=Gootenberg%2CJ&author=Keegan%2CP&author=Pazdur%2CR generate?
- What's the financial intake of http://www.fda.gov/downloads/NewsEvents/Newsroom/UCM280546.pdf?
- What's the income generated by https://doi.org/10.1038%2Fsj.bjc.6603326 each month?
- How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16967055 bring in?
- How much does http://scholar.google.com/scholar_lookup?&title=Health%20state%20utilities%20for%20metastatic%20breast%20cancer&journal=Br%20J%20Cancer&doi=10.1038%2Fsj.bjc.6603326&volume=95&issue=6&pages=683-690&publication_year=2006&author=Lloyd%2CA&author=Nafees%2CB&author=Narewska%2CJ&author=Dewilde%2CS&author=Watkins%2CJ bring in each month?
- Financial intake of https://doi.org/10.1200%2FJCO.2010.28.0982
- What's the profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21383283?
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=RIBBON-1%3A%20randomized%2C%20double-blind%2C%20placebo-controlled%2C%20phase%20III%20trial%20of%20chemotherapy%20with%20or%20without%20bevacizumab%20for%20first-line%20treatment%20of%20human%20epidermal%20growth%20factor%20receptor%202-negative%2C%20locally%20recurrent%20or%20metastatic%20breast%20cancer&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2010.28.0982&volume=29&issue=10&pages=1252-1260&publication_year=2011&author=Robert%2CNJ&author=Dieras%2CV&author=Glaspy%2CJ&author=Brufsky%2CAM&author=Bondarenko%2CI&author=Lipatov%2CON&author=Perez%2CEA&author=Yardley%2CDA&author=Chan%2CSY&author=Zhou%2CX?
- Financial intake of https://doi.org/10.1016%2Fj.ejca.2008.12.016
- What's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19147344?
- How much does http://scholar.google.com/scholar_lookup?&title=Bevacizumab%20in%20combination%20with%20paclitaxel%20for%20HER-2%20negative%20metastatic%20breast%20cancer%3A%20an%20economic%20evaluation&journal=Eur%20J%20Cancer&doi=10.1016%2Fj.ejca.2008.12.016&volume=45&issue=8&pages=1397-1406&publication_year=2009&author=Dedes%2CKJ&author=Matter-Walstra%2CK&author=Schwenkglenks%2CM&author=Pestalozzi%2CBC&author=Fink%2CD&author=Brauchli%2CP&author=Szucs%2CTD net monthly?
- How much revenue does http://www.nice.org.uk/newsroom/pressreleases/BevacizumabForMetastaticBreastCancer.jsp produce monthly?
- What's the financial outcome of http://www.pharmafeed.com/will-antibody-biosimilars-see-the-light-of-day?
- How much does https://citation-needed.springer.com/v2/references/10.1007/s10549-011-1919-y?format=refman&flavour=references generate monthly?
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Alberto%20J.%20Montero bring in each month?
- Get to know what's the income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Alberto%20J.%20Montero%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- Monthly income for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kiran%20Avancha
- How much money does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kiran%20Avancha%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
- Get to know what's the income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Stefan%20Gl%C3%BCck
- https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Stefan%20Gl%C3%BCck%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's revenue stream
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Gilberto%20Lopes net monthly?
- https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Gilberto%20Lopes%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's total income per month
- What's the total monthly financial gain of https://s100.copyright.com/AppDispatchServlet?title=A%20cost-benefit%20analysis%20of%20bevacizumab%20in%20combination%20with%20paclitaxel%20in%20the%20first-line%20treatment%20of%20patients%20with%20metastatic%20breast%20cancer&author=Alberto%20J.%20Montero%20et%20al&contentID=10.1007%2Fs10549-011-1919-y©right=Springer%20Science%2BBusiness%20Media%2C%20LLC.&publication=0167-6806&publicationDate=2011-12-27&publisherName=SpringerNature&orderBeanReset=true?
- Get to know https://citation-needed.springer.com/v2/references/10.1007/s10549-011-1919-y?format=refman&flavour=citation's earnings
- https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral's revenue stream
- Profit of https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research
- Explore the financials of https://www.springernature.com/gp/products
- What's the revenue for https://www.springernature.com/gp/librarians?
- How much profit does https://www.springernature.com/gp/societies make?
- How much income is https://www.springernature.com/gp/partners earning monthly?
- How much does https://www.springer.com/ gross monthly?
- How much does https://www.nature.com/ net monthly?
- What's the profit of https://www.biomedcentral.com/?
- How much does https://www.palgrave.com/ gross monthly?
- Earnings of https://www.apress.com/
- How much income is https://www.springernature.com/gp/legal/ccpa earning monthly?
- How much does https://www.springernature.com/gp/info/accessibility pull in monthly?
- Get to know https://support.springernature.com/en/support/home's earnings
- Financial intake of https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations
- Discover the revenue of https://www.springernature.com/
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Clipboard.js
- Prism.js
CDN Services {📦}
- Crossref